The Peptide Network between Tetanus Toxin and Human Proteins Associated with Epilepsy

Guglielmo Lucchese, 1 Jean Pierre Spinosa, 2 and Darja Kanduc 3

1 Brain and Language Laboratory, Cluster of Excellence "Languages of Emotions", Free University of Berlin, 14195 Berlin, Germany
2 Faculty of Biology & Medicine, University of Lausanne, CH-1011 Lausanne, Switzerland
3 Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, 70125 Bari, Italy

Correspondence should be addressed to Darja Kanduc; darja.kanduc@uniba.it

Received 7 March 2014; Revised 24 April 2014; Accepted 13 May 2014; Published 1 June 2014

Academic Editor: A. Vezzani

Copyright © 2014 Guglielmo Lucchese et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sequence matching analyses show that Clostridium tetani neurotoxin shares numerous pentapeptides (68, including multiple occurrences) with 42 human proteins that, when altered, have been associated with epilepsy. Such a peptide sharing is higher than expected, nonstochastic, and involves tetanus toxin-derived epitopes that have been validated as immunopositive in the human host. Of note, an unexpected high level of peptide matching is found in mitogen-activated protein kinase 10 (MK10), a protein selectively expressed in hippocampal areas. On the whole, the data indicate a potential for cross-reactivity between the neurotoxin and specific epilepsy-associated proteins and may help evaluate the potential risk for epilepsy following immune responses induced by tetanus infection. Moreover, this study may contribute to clarifying the etiopathogenesis of the different types of epilepsy.

1. Introduction

The term epilepsy defines a group of disturbances whose only recognized commonality is the paroxysmal synchronous discharging of groups of neurons. Localization and physiological function of the neuronal populations involved determine the clinical picture, so that (1) clinical manifestations can be extremely subtle and the diagnosis can be challenging also in terms of differential definition; (2) epilepsy(ies) can produce extremely multiformal clinical pictures with a large degree of overlap [1–3]. Indeed, epileptic syndromes can also be embedded in larger syndromic clinical pictures, that is, West and Lennox-Gastaut syndromes in tuberous sclerosis complex [4, 5]. This clinical diversity has noteworthy nosological implications. Syndromic or disease status of various forms of epilepsy and the terminology used to define them are indeed still matter of debate [7–9]. Likewise, the molecular etiopathogenesis of epilepsies has to be better defined at the molecular level. Although genetic alterations [10–12], inflammation [13], and viral infections [14–16] have been considered and thoroughly studied, nonetheless, the molecular basis and the causal mechanisms of epilepsies are still unclear.

Recently, research on epilepsy has also outlined a neurodevelopmental context [17–21]. Spontaneous recurrent seizures have been observed after induction of status epilepticus during the second and third postnatal weeks in rodents, by use of chemoconvulsants such as pilocarpine, kainate, and tetanus toxin (TT) [22]. TT seizures as well as experimental febrile seizures and developmental lithium pilocarpine appear to share a common mechanism for enhancing hippocampal network excitability and promoting epilepsy, possibly through alterations in neurotransmitter receptors or voltage-gated ion channels ([23] and further references therein).

Moreover, numerous reports suggest that immune mechanisms might play a role in processes leading to epileptogenesis [15, 24–32]. In fact, antibodies against neural antigens involved in neurotransmission have been detected in epileptic subjects [33–39], and, remarkably, epilepsy was shown to respond to immunotherapeutic approaches [38, 40, 41]. Finally, population-based cohort studies have documented
that microbial infections during pregnancy may be a risk factor for epilepsy in offspring [42–45].

In such a multifaceted scientific-clinical context, here we analyze the peptide commonality between TT, a powerful neurotoxin used in animal models of experimental epilepsy [46–50], and human antigens that have been related to epilepsy, searching for possible immunological link(s) that might contribute to epileptogenesis. Indeed, a massive peptide overlap characterizes microbial and human proteomes [51–54] and gives grounds for questioning whether immune response(s) to microbial infections might potentially result in cross-reactions against neuronal antigens [55–58]. Pathogen versus human immune cross-reactivity might contribute to explaining the association between microbial infections and neurological syndromes [59] and assumes a special significance during pregnancy in light of the consequent possible neurodevelopmental alterations in the fetus and offspring [26, 58].

We report that the tetanus neurotoxin and human epilepsy antigens share an ample pentapeptide platform. The bacterial versus human peptide overlap is not random and, importantly, a search through the Immune Epitope Database (IEDB; http://www.immuneepitope.org/) reveals that the shared pentapeptides are part of TT-derived epitopes. The latter datum is relevant also in light of the role of pentapeptides as minimal functional units in cell biology and immunology [60, 61]. On the whole, the results support the possibility that immune cross-reactions may occur between TT and epilepsy-related proteins.

2. Methods

TT protein sequence, UniProtKB/Swiss-Prot accession number: P04958, 1315aa long, from Clostridium tetani (NCBI Taxonomic identifier: 212717; further details at http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi) was analyzed for pentapeptide sharing with epilepsy-associated proteins as follows. First, a pentapeptide library was constructed by dissecting the TT primary sequence into pentapeptide offsets by one residue, that is, MPITI, PITIN, ITINN, TINNF, INNFR, and so forth. Then, each of the final 1311 pentamers was analyzed for instances of the same match within a library consisting of primary sequences of human proteins that, when altered, have been associated with epilepsy. The number of matches and the human proteins sharing matches were recorded.

Epilepsy-associated proteins were randomly retrieved from UniProtKB Database (http://www.uniprot.org/). An unbiased set of proteins that on whatever basis (i.e., differential regulation, protein modification, or mutation) had been involved in or related to epilepsy was obtained utilizing “epilepsy” and “Homo sapiens” as keywords. Only canonical protein sequences were considered. At the time of this study, the keyword-guided search produced a library of 133 human UniProt entries, for a total of 106,022aa. Epilepsy-associated proteins are reported as UniProtKB/Swiss-Prot entry names throughout the paper, unless when discussed in detail. Any pentapeptide occurrence in the set of epilepsy-associated proteins was termed a match.

A set of proteins associated with Down syndrome, a genetic disease in which infectious agents have no role, was retrieved from UniProtKB Database and used as a comparison sample. This set was formed by the following proteins listed according to the aa length, with UniProtKB/Swiss-Prot entries in parentheses: (1) Down syndrome critical region protein 10 (P59022, DSC10), 87aa; (2) Down syndrome critical region protein 8 (Q96T75, DSCR8), 97aa; (3) Down syndrome critical region protein 4 (P56555, DSCR4), 118aa; (4) Down syndrome critical region protein 9 (P59020, DSCR9), 149aa; (5) Down syndrome critical region protein 5 or phosphatidylinositol N-acetylgalactosaminyltransferase subunit P (P57054, PIGP), 158aa; (6) Down syndrome critical region protein 6 or protein ripply3 (P57055, DSCR6), 190aa; (7) Down syndrome candidate region 1- like 1 or regulator of calcineurin 2 (Q14206, RCAN2), 197aa; (8) Down syndrome candidate region 1-like protein 2 or regulator of calcineurin 3 (Q9UKA8, RCAN3), 244aa; (9) Down syndrome critical region protein 1 or regulator of calcineurin 1 (P55805, RCAN1), 252aa; (10) Down syndrome critical region protein 2 or proteasome assembly chaperone 1 (O95456, PSMG1), 288aa; and (11) Down syndrome critical region protein 3 (O14972, DSCR3), 297aa.

The Immune Epitope Database (IEDB; http://www.immuneepitope.org/) was used to search for TT-derived B- and/or T-cell epitopes that had been experimentally validated as positive in the human host.

Expected occurrences for pentapeptide sharing between C. tetani neurotoxin and human proteins associated with epilepsy were calculated as follows. First, we considered the number of all possible pentapeptides, \(N\). Since each residue can be any of 20aa, the number of all possible pentapeptides \(N\) is given by \(N = 20^5 = 3.2 \times 10^5\). Next, we considered the TT and epilepsy-associated proteins as two sets of pentapeptide size \(m\) and \(n\). That is, \(m\) is the number of pentapeptides present in the TT protein and \(n\) is the number of pentapeptides present in the epilepsy-associated protein set. If \(X\) is the number of times a pentapeptide is selected in the TT protein of size \(m\) and \(Y\) is the number of times the same pentapeptide is selected in the epilepsy-associated protein set, then \(X = m/N\) and \(Y = n/N\). Assuming that \(X\) and \(Y\) are independent, \(XY = mn/N^2\). In other words, the expected number of times that one pentapeptide will be selected simultaneously in both TT and epilepsy-related protein set is given by \(mn/N^2\). Neglecting the relative abundance of aa and assuming \(m \ll N\) and \(n \ll N\), we obtain a formula derived by approximation where the total number of occurrences in a second sample \(n\) (the epilepsy-related protein set) of pentapeptides occurring in the first sample \(m\) (TT) is given by \(mn/N + m/2\).

3. Results and Discussion

3.1. Description of the Pentapeptide Sharing between TT and Epilepsy-Associated Proteins. Peptide sharing between TT and human epilepsy-associated proteins was analyzed using (1) the pentapeptide module as a matching probe and (2) a library consisting of 133 epilepsy-related protein sequences retrieved from UniProt (see under Methods).
We used pentapeptides as scanning probes in sequence similarity analyses since a grouping of five aa residues may represent a minimal unit of immune recognition in cellular and humoral responses. Indeed, scientific literature indicates that an optimal peptide length for T-cell epitopes ranges between 9 and 15 residues, with the central 5–7 aa representing the specific immune recognition contacts and the flanking residues determining the binding potential to the MHC molecules [62–66]. De facto, the HFMP pentapeptide was reported to be a minimal antigenic determinant for MHC class I-restricted T lymphocytes [65], while the KYVKQ pentapeptide was demonstrated to be a minimal antigenic determinant for CD4(+) T-cell clones [66]; in addition, the IEDB describes numerous pentapeptide epitopes capable of binding MHC molecules (e.g., epitope IEDB IDs: 5740, 7948, 11514, 25472, and 33701) and inducing T-cell proliferation (e.g., epitope IEDB IDs: 815, 40168, 47974, 59947, 107725, 107725, and 110376) (reviewed in [61]). Likewise, humoral immune recognition/reactivity unfolds around short aa motifs ([67–70]; reviewed in [71]). A representative example is a report by Zeng and colleagues [70], according to which the C-terminal pentapeptide (aa sequence: GLRPG) of luteinizing hormone-releasing hormone is a dominant B-cell epitope able to elicit a strong anti-LHRH antibody response and to discriminate between anti-LHRH antibodies present in fertile and nonfertile mice. That is, the pentapeptide GLRPG has immunogenic and antigenic properties and also discriminates antibody specificities associated with reproductive competence.

The analyzed set of 133 human proteins related to epilepsy is listed in Box 1 according to the aa size (i.e., from IR3IP or immediate early response 3-interacting protein 1, 82aa, to GPR98 or monogenic audiogenic seizure susceptibility protein 1 homolog, 6306aa).

Following matching analyses, we found that 42 out of the 133 epilepsy-associated proteins retrieved at random from UniProt database share 58 pentapeptides (68 including multiple occurrences) with the bacterial toxin. Box 2 lists the epilepsy-related proteins that share pentapeptides with TT and the shared pentapeptides. No TT pentapeptide match was found in the comparison set of proteins associated with Down syndrome.

3.2. Nonstochasticity of the Pentapeptide Sharing between TT and Epilepsy-Associated Proteins. The comparative analysis of Boxes 1 and 2 highlights three main points. Firstly, the 68 TT pentapeptide overlap described in Box 2 exceeds the expected value. As detailed under Methods, the expected number of TT pentapeptides that may occur in the epilepsy-related protein set is given by \( mnN + m/2 \), where \( m \) is the number of pentapeptides contained in TT (1,311), \( n \) is the number of pentapeptides contained in the epilepsy-related protein set (105,490), and \( N \) is the number of all possible pentapeptides (20^5). Developing the equation gives 43 as expected number of pentapeptide matches, whereas the observed value is 68 (see Box 2). That is, the pentapeptide overlap between TT and epilepsy-related proteins is 1.58 times higher when compared to the expected one.

A second point of note is that the distribution of the pentapeptide overlap through the epilepsy-related proteins is unexpected. According to equation described above, pentapeptide sharing between two samples is as a quantity directly proportional to the number of pentapeptides in the analyzed samples; that is, it is proportional to the protein aa size. Actually, 91 epilepsy-related proteins are excluded from the pentapeptide matching with TT, independently of their length. For example, SPTN1, 2472aa (see Box 1), has no bacterial matches, while LRRCL, 524aa, shares 3 pentapeptides with TT (Box 2).

In summary, a comparative analysis of Boxes 1 and 2 highlights that 68 TT pentapeptide matches are allocated in 42 out 133 human proteins that have been related, when altered, to epilepsy, and no relationship appears to exist between pentapeptide sharing and the human protein size. Applying the equation described above to the set of 42 epilepsy-related proteins sharing 68 pentapeptides with TT and amounting to 50,254aa, the expected pentapeptide overlap is equal to 20, so that the observed occurrence value is 3, 4 times higher.

Finally, a third punctum saliens is that nonrandomness characterizes also the distribution of the TT pentapeptides among the 42 epilepsy-associated proteins. Box 2 shows that a few TT pentapeptides are repeated in the 42 epilepsy-associated protein set. Indeed, TT pentapeptides E1IP5, SL5G, and FCKAL recur twice, and TT pentapeptides FGGQD, KEIEK, and TFLRD occur three times (Box 2; see pentapeptides underlined). Box 2 also shows that MK10 (mitogen-activated protein kinase 10; 464aa); CDKL5 (cyclin-dependent kinase-like 5; 1030aa); and KCMA1 (calcium-activated potassium channel subunit alpha-1; 1256aa) share two sequentially overlapping pentapeptides with TT, that is, share the hexapeptides SVDDAL, KNSFSE, and PKEIEK, respectively. The nonrandom TT pentapeptide sharing clearly emerges from Figure 1, where expected and observed occurrence values are graphically compared.

It can be seen that, in conflict with the theoretical trend of the TT pentapeptide matching as a function of epilepsy-related protein length (Figure 1, columns in gray), the observed to expected ratio of pentapeptide matching shows no relationship with the human protein length (Figure 1, columns in black). For example, contrary to mathematical expectations, MK10 (464aa long) has three pentapeptide matches, whereas VP13A (3174aa long) has one match (see Box 2 and Figure 1).

3.3. Immunologic Potential of the Pentapeptide Sharing between TT and Epilepsy-Associated Proteins. Having defined the TT versus epilepsy-associated proteins pentapeptide overlap, it was next tested whether such a sharing has an immunologic potential. To this aim we used IEDB, a database that describes B- and T-cell epitopes for humans, nonhuman primates, rodents, and other animal species, and searched for TT-derived epitopes that had been validated as immunopositive in humans. At the time of the search, we obtained a list of 517 TT-derived epitopes. The pentapeptides common to epilepsy-associated proteins and TT (see Box 2, sequences in italic) were used as probes to scan the 517 TT-derived epitope set in order to define potential cross-reactive peptide sequences. Results are reported in Table 1.
Box 1: List of the 133 epilepsy-associated proteins analyzed for TT pentapeptide sharing. Proteins were randomly retrieved from UniProtKB (http://www.uniprot.org/) as described under Methods. Proteins are indicated by UniProtKB/Swiss-Prot entry names, and listed according to increasing aa length reported in parentheses.

Box 2: Peptide sharing between TT and epilepsy-associated proteins. Proteins reported by UniProtKB/Swiss-Prot entry names and listed according to the aa length. Pentapeptides shared with TT are italic in parentheses. Pentapeptides present more than once in the epilepsy antigen set are underlined. Sharing of two consecutively overlapped pentapeptides (i.e., a hexapeptide) is indicated by an asterisk.

Figure 1: Observed versus expected pentapeptide matching between TT and epilepsy-related proteins. The 42 proteins sharing pentapeptides with TT are allocated along the x-axis according to increasing aa length. Gray columns: expected matches calculated according to the formula mnn + m/2, where m is the number of pentapeptides present in the neurotoxin (1,311) and n is the number of pentapeptides present in the epilepsy-associated protein (see Methods). For example, in the case of IR3IP protein, 82aa, the possible pentapeptide overlap is equal to 1,311 × 78/3,200,000 + 1,311/2. Black columns: observed to expected ratio of the pentapeptide matching. Observed matching values from Box 2.
In essence, Table 1 shows that all of the 58 pentapeptides common to the 42 epilepsy-associated proteins and TT (Box 2, peptide sequences in parentheses and in italic) are present in 116 TT-derived epitopes that had been established to be immunopositive in humans. This datum indicates a potential vulnerability of the 42 epilepsy-associated proteins to cross-reactions following anti-TT immune responses. Moreover, many TT-derived epitopes share fragments with distinct epilepsy-related proteins and are of particular significance to a multiple cross-reactivity risk, since, for example, an immune response targeting the TT epitope fnmtVS-FWLRVPKVsahle (see Table 1, IEDB ID 17207, with shared fragments in capital letter) has the potential to cross-react with the following three crucial proteins related to different forms of epilepsy:

- (i) GBRAl or gamma-aminobutyric acid receptor subunit alpha-1, the major inhibitory neurotransmitter in the vertebrate brain that mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel [72],
- (ii) SCN8A or voltage-gated sodium channel subunit alpha Nav1.6, a protein that mediates the voltage-dependent sodium ion permeability of excitable membranes [73],
- (iii) EFHC1 or myoclonin-1, a protein that may enhance calcium influx through CACNA1E and stimulate programmed cell death [74].

Such a multiple cross-reactivity potential is shown also by other TT-derived epitopes, eg, epitopes IEDB IDs 30436, 48049, I13407, and so forth.

Also, it seems important to highlight that MK10 (mitogen-activated protein kinase 10, also known as stress-activated protein kinase JNK3 or p493F12 kinase), a protein that shows the highest unexpected level of pentapeptide overlap to TT (Figure 1) and also has a high immunologic potential as illustrated in Table 1 (i.e., MK10 pentapeptide(s) are present in 7 TT-derived epitopes), is selectively expressed in a subpopulation of pyramidal neurons in the CA1, CA4, and subiculum regions of the hippocampus, and layers 3 and 5 of the neocortex [75]. That is, there is a potential cross-reactivity risk specifically allocated in brain areas directly linked to epileptogenesis [76, 77].

4. Conclusions

This study describes a vast pentapeptide commonality between TT-derived epitopes and epilepsy-associated proteins. This peptide sharing acquires a relevant pathologic potential in light of the fact that pentapeptide modules have the capacity of inducing immune response(s) and are main players in immune recognition [61–71]. Immunologically, two sequences that share a pentapeptide are potentially subject to a cross-reaction [60].

In the disease model examined here, that is, tetanus infection and epilepsy, the ample cross-reactivity platform between TT-derived epitopes and human epilepsy-associated antigens supports the hypothesis of an immune involvement in epilepsy. As a matter of fact, all the 42 epilepsy-related proteins listed in Box 2 are potential targets of cross-reactions (see Table 1). Qualitatively, the peptide overlap occurs in human proteins canonically associated with epilepsy such as gamma-aminobutyric acid receptor subunit alpha-1 (GBRA1), gamma-aminobutyric acid type B receptor subunit 1 (GABRI), sodium channel protein subunits (SCN1A, SCN2A, SCN8A, and SCN9A), and calcium-activated potassium channel subunit alpha-1 (KCMAl) (Table 1). Obviously, an immune attack against such epilepsy-associated proteins may cause alterations to neural structures and functions, especially when the neurodevelopmental intrauterine phase is considered. Being of nonsecondary importance, the non-stochastic character of the peptide overlap between TT and epilepsy-associated proteins (Figure 1) indicates that the potential cross-reactivity extent (and the associated risk of developing epilepsy and neurodevelopmental disorders) will increase with the number of anti-TT immune stimulations.

An additional relevant point is the “antigenic patchwork” shown in Table 1. Indeed, the potential peptide crossreactome involved in different extent and in different combinations of 42 epilepsy-associated proteins might help understand the complex neurobiological network that, once hit and perturbed, may underlie different epileptic forms [1–9]. Also, it has to be noted that Table 1 includes proteins such as CNTP2 or contactin-associated protein-like 2, RELN or reelin, and TSC1 or tuberous sclerosis 1 protein, which are also landmark antigens for autism and the associated impairment in communication/language skills and behaviors [78–81]. Hence, Table 1 may provide a mechanistic framework to allocate the occurrence of epilepsy, intellectual disability, and autism spectrum disorder in patients with tuberous sclerosis complex. Likewise, data from Table 1 might contribute to answering a critical question in neuropsychopathology, that is, the coexistence of patients with combined schizophrenia and epilepsy [82–85]. Indeed, Table 1 substantiates the hypothesis according to which the thread joining epilepsy and schizophrenia may reside in neurodevelopmental molecules such as leucine-rich glioma inactivated (LGI) proteins and GPR98, a G protein-coupled receptor, originally known as VGLR1 or very large G protein-coupled receptor [86]. De facto, Table 1 shows that fragments from LGI1, LGI2, and GPR98 are present in 1, 7, and 18 TT-derived epitopes, respectively. In other words, the potential cross-reactivity targeting LGI1, LGI2, and GPR98 following an anti-TT response is high.

Given the caveat that peptide immunoreactivity is influenced by numerous factors, for example, binding affinity [87], cripticity (i.e., determinants embedded in membrane structures do not induce immune responses under physiological conditions) [88], and posttranslational modifications (i.e., citrullination) [89], the present data might contribute to further our understanding of epilepsies. In particular, data from Table 1 might represent a peptide platform to be tested in antibody binding assays using sera from epileptic subjects. Accompanied by parallel immunoassays based on the utilization of epilepsy-related proteins as antigens, such an approach might not only validate the TT-epilepsy link proposed in this study, but also lead to a definition at
### Table 1: Pentapeptide sharing between TT-derived epitopes and human epilepsy-associated proteins.

<table>
<thead>
<tr>
<th>IEDB ID</th>
<th>TT-derived epitope</th>
<th>Immune context</th>
<th>Epilepsy-associated proteins</th>
</tr>
</thead>
<tbody>
<tr>
<td>1270</td>
<td>afcpeyptfdrvietNTISL</td>
<td>HLA-Class II, allele undetermined</td>
<td>ACHA2</td>
</tr>
<tr>
<td>1389</td>
<td>afriVDSGSGLVSkig</td>
<td>HLA-Class II, allele undetermined</td>
<td>GPR98 D2HDH EPMIP</td>
</tr>
<tr>
<td>1501</td>
<td>agevrqifTRDLpdkfnayl</td>
<td>HLA-Class II, allele undetermined</td>
<td>CLCN2</td>
</tr>
<tr>
<td>1929</td>
<td>aihlvnnesseVIVkKamdi</td>
<td>HLA-DRB1*04:01</td>
<td>CLN5</td>
</tr>
<tr>
<td>2219</td>
<td>akqkplefDTQSKnlmqqyi</td>
<td>HLA-Class II, allele undetermined</td>
<td>SCN8A</td>
</tr>
<tr>
<td>3156</td>
<td>almnlifiifgpPVLNKN KVEV</td>
<td>HLA-Class II, allele undetermined</td>
<td>ASAH1 LRRCl</td>
</tr>
<tr>
<td>3418</td>
<td>anskfigiteLKKLe sskink</td>
<td>HLA-DRB1*11:01</td>
<td>TSC1</td>
</tr>
<tr>
<td>3832</td>
<td>apsyTNGKlniyyrlyngl</td>
<td>HLA-DRB5<em>01:01, HLA-DRB1</em>13:01</td>
<td>WDR62</td>
</tr>
<tr>
<td>7603</td>
<td>danLISIDikndlyektl</td>
<td>HLA-DRB1*03:01</td>
<td>GPR98</td>
</tr>
<tr>
<td>8734</td>
<td>dinndissidSGFNSv sity</td>
<td>HLA-DRB1*01:01</td>
<td>GPR98</td>
</tr>
<tr>
<td>8778</td>
<td>diSGFNSv sity pdaqv pg</td>
<td>HLA-DRB1*15:01</td>
<td>GPR98</td>
</tr>
<tr>
<td>8903</td>
<td>dksidvstipvig PALNtv</td>
<td>HLA-DPB1<em>04:01, HLA-DRB1</em>15:01</td>
<td>NMDE1</td>
</tr>
<tr>
<td>9297</td>
<td>dlrtfaeKNSFEepqoei</td>
<td>HLA-DRB1*01:01</td>
<td>CDKL5</td>
</tr>
<tr>
<td>9595</td>
<td>DPALLmheLIHV Lhglyg</td>
<td>HLA-DR2, HLA-Class II, allele undetermined</td>
<td>AFG32 CLN6 WDR62</td>
</tr>
<tr>
<td>10472</td>
<td>drLSSANlyingvlns aei</td>
<td>HLA-DR2, HLA-Class II, allele undetermined</td>
<td>GPR98</td>
</tr>
<tr>
<td>11980</td>
<td>DTQSKnl qyikanskf figiteLKKL e s kink</td>
<td>HLA-Class II, allele undetermined</td>
<td>SCN8A TSC1</td>
</tr>
<tr>
<td>13095</td>
<td>eLIHV Lhglygmqvss</td>
<td>HLA-DR2, HLA-Class I, allele undetermined</td>
<td>WDR62</td>
</tr>
<tr>
<td>13125</td>
<td>eLKKLe sskinkv stpipfs</td>
<td>HLA-Class II, allele undetermined</td>
<td>TSC1</td>
</tr>
<tr>
<td>1381</td>
<td>eqdpsgattksamlnlififggpPVLNKN KVE</td>
<td>HLA-Class II, allele undetermined</td>
<td>ASAH1 LRRCl</td>
</tr>
<tr>
<td>15087</td>
<td>eysiesmsk kHSLSIGS Gwsval</td>
<td>HLA-Class II, allele undetermined</td>
<td>PWP2 GCP6 CDKL5 RELN</td>
</tr>
<tr>
<td>15411</td>
<td>fdksdnGQYIVnedkqfily</td>
<td>HLA-Class II, allele undetermined</td>
<td>PWP2</td>
</tr>
<tr>
<td>16155</td>
<td>fiaeKNSFE epqdeo vsynkt</td>
<td>B-cell</td>
<td>CDKL5</td>
</tr>
<tr>
<td>17134</td>
<td>fnaylankwvfTTTNDrls</td>
<td>HLA-Class II, allele undetermined</td>
<td>NHC1</td>
</tr>
<tr>
<td>17205</td>
<td>fmnftVSFWL RVPK</td>
<td>HLA-Class II, allele undetermined</td>
<td>GBRA1 SCN8A</td>
</tr>
<tr>
<td>17206</td>
<td>fmnftVSF WL RVPK sahle</td>
<td>HLA-DR3</td>
<td>GBRA1 SCN8A EFHC1</td>
</tr>
<tr>
<td>17207</td>
<td>fmnftVSF WL RVPK sahle</td>
<td>HLA-DRB1*11:01, HLA-DR, HLA-DR1, HLA-DR5, HLA-DR7, HLA-DR11, HLA-DPw4, HLA-Class II, allele undetermined</td>
<td>GBRA1 SCN8A EFHC1</td>
</tr>
<tr>
<td>17208</td>
<td>fmnftVSF WL RVPK sahle</td>
<td>HLA-DRB1<em>01:01, HLA-DRB1</em>04:01, HLA-DRB1<em>07:01, HLA-DRB1</em>11:01</td>
<td>GBRA1 SCN8A EFHC1</td>
</tr>
<tr>
<td>17487</td>
<td>fqilnSIMYGFTel egkk</td>
<td>HLA-Class II, allele undetermined</td>
<td>SL9A6 SL9A9 LGI1</td>
</tr>
<tr>
<td>18217</td>
<td>fvkSGDFIK Lyvysmmnehivgy</td>
<td>HLA-Class II, allele undetermined</td>
<td>EFHC2 CNTP2</td>
</tr>
<tr>
<td>18356</td>
<td>fwLRPKV sahleqqy</td>
<td>HLA-DRB1*11:01</td>
<td>SCN8A EFHC1</td>
</tr>
<tr>
<td>19469</td>
<td>gevqriTFRDL pdkfnaylankw</td>
<td>B-cell</td>
<td>CLCN2</td>
</tr>
<tr>
<td>21599</td>
<td>gpdkcfquadeinnlnklKLEEkan</td>
<td>B-cell</td>
<td>ARHG9</td>
</tr>
<tr>
<td>22769</td>
<td>gtneyissmmsk HSLIS G</td>
<td>HLA-Class II, allele undetermined</td>
<td>DQB1<em>06:02, DRB5</em>01:01</td>
</tr>
<tr>
<td>24238</td>
<td>hLKDKIlgcdwvftepdegwntd</td>
<td>HLA-Class II, allele undetermined</td>
<td>ROGD1</td>
</tr>
<tr>
<td>25597</td>
<td>idksidvstipvigPALNI</td>
<td>HLA-Class II, allele undetermined</td>
<td>NMDE1</td>
</tr>
<tr>
<td>25666</td>
<td>ids vfs GDFIK Lyvysynn</td>
<td>HLA-DRB1*15:01</td>
<td>EFHC2 CNTP2</td>
</tr>
<tr>
<td>26808</td>
<td>ikknedlfiac KNSFE ee</td>
<td>HLA-Class II, allele undetermined</td>
<td>CDKL5</td>
</tr>
<tr>
<td>27639</td>
<td>ingkaihvnnesseVIVHK</td>
<td>HLA-Class II, allele undetermined</td>
<td>CLN5</td>
</tr>
<tr>
<td>IEDB ID</td>
<td>TT-derived epitope</td>
<td>Immune context</td>
<td>Epilepsy-associated proteins</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------</td>
<td>----------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>29241</td>
<td>ivdynlqskiTLPNDrttpv</td>
<td>HLA-Class II, allele undetermined</td>
<td>GPR98</td>
</tr>
<tr>
<td>29331</td>
<td>ivkQGYEGnf</td>
<td>HLA-Class II, allele undetermined</td>
<td>TSEAR</td>
</tr>
<tr>
<td>29407</td>
<td>ivpyigPALNiv</td>
<td>HLA-Class II, allele undetermined</td>
<td>NMDE1</td>
</tr>
<tr>
<td>29408</td>
<td>ivpyigPALNvakQGYEGnf</td>
<td>HLA-DRB1*15:01</td>
<td>NMDE1 TSEAR</td>
</tr>
<tr>
<td>29843</td>
<td>KAKWlgtvntqfKSRqYq</td>
<td>HLA-Class II, allele undetermined</td>
<td>LG12 WDR62</td>
</tr>
<tr>
<td>29891</td>
<td>kamdierNDMFNilvSVFLrnp</td>
<td>B-cell</td>
<td>SCN9A GBRA1</td>
</tr>
<tr>
<td>30269</td>
<td>kvQVLKlnidymyltnapsy</td>
<td>HLA-DRB1<em>01:01, HLA-DRB1</em>04:01</td>
<td>GPR98</td>
</tr>
<tr>
<td>30436</td>
<td>KEIEKlyrSYL kínhFLRDwpnpg</td>
<td>B-cell</td>
<td>SCMD3 KCMA1 GCP6 GTR1</td>
</tr>
<tr>
<td>30572</td>
<td>keqiaidinlnkKLEEkan</td>
<td>HLA-Class II, allele undetermined</td>
<td>ARHG9</td>
</tr>
<tr>
<td>32521</td>
<td>knitdymyltnapsyTNGKL</td>
<td>HLA-Class II, allele undetermined</td>
<td>WDR62</td>
</tr>
<tr>
<td>32546</td>
<td>knldcwvdneEDIDVlkstkstil</td>
<td>B-cell</td>
<td>GABRI</td>
</tr>
<tr>
<td>33527</td>
<td>kstlnlnndiisidSGFNSs</td>
<td>B-cell</td>
<td>GPR98</td>
</tr>
<tr>
<td>34301</td>
<td>kwievvyKLAKVAGWtqntq</td>
<td>HLA-DRB1*01:01</td>
<td>ARHGA LG12</td>
</tr>
<tr>
<td>34887</td>
<td>lankwvflITNDrLSANlyin</td>
<td>B-cell</td>
<td>NHLC1 GPR98</td>
</tr>
<tr>
<td>35058</td>
<td>lickikndflfaeKNSFS</td>
<td>HLA-DRB1*04:01</td>
<td>CDKL5</td>
</tr>
<tr>
<td>35566</td>
<td>lekryekwievyyKLAKWk</td>
<td>HLA-Class II, allele undetermined</td>
<td>ARHGA LG12</td>
</tr>
<tr>
<td>35993</td>
<td>lrfFGGQDanLISIDlndkdl</td>
<td>HLA-Class II, allele undetermined</td>
<td>SCN1A SCN2A SCN8A GPR98</td>
</tr>
<tr>
<td>36667</td>
<td>lipvasssdvQLKLnidym</td>
<td>HLA-DRB1*11:01</td>
<td>GPR98</td>
</tr>
<tr>
<td>38977</td>
<td>lqrTMNSVDDALInstki</td>
<td>HLA-Class II, allele undetermined</td>
<td>VP13A MK10</td>
</tr>
<tr>
<td>40770</td>
<td>lymgvssheEIIPkqey</td>
<td>HLA-Class II, allele undetermined</td>
<td>ACH24 ACH4</td>
</tr>
<tr>
<td>4152</td>
<td>mfnftVSFLRVPKVasah</td>
<td>HLA-DRB1*11:01</td>
<td>GBRA1 SCN8A EFHC1</td>
</tr>
<tr>
<td>42847</td>
<td>mtnSVDDALInstkiylyf</td>
<td>HLA-DRB1*11:01</td>
<td>MK10</td>
</tr>
<tr>
<td>43280</td>
<td>napsyTNGIKlniyyrrlqgklf</td>
<td>B-cell</td>
<td>WDR62</td>
</tr>
<tr>
<td>43359</td>
<td>ndrLSANlyningvlmsae</td>
<td>HLA-Class II, allele undetermined</td>
<td>GPR98</td>
</tr>
<tr>
<td>43591</td>
<td>neEDIDVlkstkstlindin</td>
<td>HLA-Class II, allele undetermined</td>
<td>GABRI</td>
</tr>
<tr>
<td>43939</td>
<td>nftVSFLRVPK</td>
<td>HLA-Class II, allele undetermined</td>
<td>GBRA1 SCN8A</td>
</tr>
<tr>
<td>43940</td>
<td>nftVSFLRVPKVasah</td>
<td>HLA-DRB1*11:01</td>
<td>GBRA1 SCN8A EFHC1</td>
</tr>
<tr>
<td>44007</td>
<td>ngkaihvnnessVIVHKamdi</td>
<td>B-cell</td>
<td>CLN5</td>
</tr>
<tr>
<td>44396</td>
<td>nivkQGYEGnfi</td>
<td>HLA-Class II, allele undetermined</td>
<td>TSEAR</td>
</tr>
<tr>
<td>44200</td>
<td>niddntiyqlyqaqSKPTTL</td>
<td>HLA-DRB1*01:01</td>
<td>SL9A6</td>
</tr>
<tr>
<td>44383</td>
<td>NITSltigksyqfDPAcLall</td>
<td>HLA-Class III, allele undetermined</td>
<td>ACH24 AFG32 CLN6</td>
</tr>
<tr>
<td>44557</td>
<td>NKNEvrtvrlvdnknlyrpf</td>
<td>HLA-Class II, allele undetermined</td>
<td>LRRC1</td>
</tr>
<tr>
<td>44667</td>
<td>nldinndisdiISGFNSsvi</td>
<td>HLA-Class II, allele undetermined</td>
<td>GPR98</td>
</tr>
<tr>
<td>45102</td>
<td>nfnfVSFLRVPKVasah</td>
<td>HLA-Class II, allele undetermined</td>
<td>GBRA1 SCN8A EFHC1</td>
</tr>
<tr>
<td>46136</td>
<td>ntiyqlyqaqSKPTTLqirit</td>
<td>HLA-Class II, allele undetermined</td>
<td>SL9A6</td>
</tr>
<tr>
<td>46853</td>
<td>PALLmheLIHVHLghlygmpq</td>
<td>HLA-Class II, allele undetermined</td>
<td>CLN6 WDR62</td>
</tr>
<tr>
<td>46855</td>
<td>PALNvkkQGYEGnfigalet</td>
<td>HLA-Class II, allele undetermined</td>
<td>NMDE1 TSEAR</td>
</tr>
<tr>
<td>48049</td>
<td>PKEIEKlyrSYL kínhFLRDF</td>
<td>HLA-Class II, allele undetermined</td>
<td>GCP6 CSMD3 KCMA1 GTR1</td>
</tr>
<tr>
<td>48697</td>
<td>pnrdsilaswmyfhnLKDPIlgc</td>
<td>B-cell</td>
<td>ROGDJ</td>
</tr>
<tr>
<td>49984</td>
<td>pvtkGIPAYapeksnaasteth</td>
<td>B-cell</td>
<td>CBPA6</td>
</tr>
<tr>
<td>51254</td>
<td>qksPTTLqirtMTNSVDDALins</td>
<td>B-cell</td>
<td>SL9A6 VP13A MK10</td>
</tr>
<tr>
<td>56528</td>
<td>ryekwievyyKLAKVAKWtqtq</td>
<td>B-cell</td>
<td>ARHGA LG12</td>
</tr>
<tr>
<td>57935</td>
<td>sfvksGDFKlVlyvynneh</td>
<td>HLA-Class II, allele undetermined</td>
<td>EFHC2 CNTP2</td>
</tr>
<tr>
<td>57947</td>
<td>sfwLRVPKVsashle</td>
<td>HLA-DR5, HLA-DRB1*11:01</td>
<td>SCN8A EFHC1</td>
</tr>
<tr>
<td>58527</td>
<td>SIGSsvslgkmnliwltlk</td>
<td>HLA-DRB1*03:01</td>
<td>RELN</td>
</tr>
<tr>
<td>59500</td>
<td>SLTDLggeclicikin</td>
<td>HLA-Class II, allele undetermined</td>
<td>LRRC1</td>
</tr>
</tbody>
</table>
One hundred and sixteen linear TT-derived epitopes that had been found to be immunopositive in the human host were analyzed. Epitope number refers to IEDB ID. Further details and references are reported in the Immune Epitope Database (IEDB; http://www.immuneepitope.org/).

The molecular level of the repeatedly advanced association between antibodies and epilepsy [33–41]. Moreover, of not less importance, immunoassay validation could also represent a prelude to specific therapies based on peptide modules able to block epileptogenic anti-TT autoantibodies [38–41, 90]. Immunological research in this direction has been programmed in our lab.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Table 1: Continued.

<table>
<thead>
<tr>
<th>IEDB ID</th>
<th>TT-derived epitope</th>
<th>Immune context</th>
<th>Epilepsy-associated proteins</th>
</tr>
</thead>
<tbody>
<tr>
<td>61214</td>
<td>ssmmkHSLSIGGwsvslkg</td>
<td>HLA-Class II, allele undetermined</td>
<td>PWP2 GCP6 CDKL5 RELN</td>
</tr>
<tr>
<td>61354</td>
<td>ssdkDVQLKntidymltnapsy</td>
<td>B-cell</td>
<td>GPR98</td>
</tr>
<tr>
<td>62073</td>
<td>SVDDALinstkiysyfpsvisvkqNGAIGII</td>
<td>HLA-Class II, allele undetermined</td>
<td>MK10</td>
</tr>
<tr>
<td>63277</td>
<td>tdymtnapsyTNGKLnisy</td>
<td>HLA-DRB1<em>01:01, HLA-DRB1</em>04:01</td>
<td>WDR62</td>
</tr>
<tr>
<td>63450</td>
<td>telKKLeskinkvfstpipf</td>
<td>HLA-DRB1*07:01</td>
<td>TSC1</td>
</tr>
<tr>
<td>64514</td>
<td>tiyndhEGFNIESKDLksey</td>
<td>HLA-Class II, allele undetermined</td>
<td>CSMD3 GPR98</td>
</tr>
<tr>
<td>65324</td>
<td>TNGKLniiyyryrnlkgfii</td>
<td>HLA-Class II, allele undetermined</td>
<td>WDR62</td>
</tr>
<tr>
<td>67104</td>
<td>tvntqfqKRSYQmysresentyda</td>
<td>B-cell</td>
<td>WDR62</td>
</tr>
<tr>
<td>67147</td>
<td>tVSPWLVRPKVsasa</td>
<td>HLA-DRB1<em>11:01, HLA-DRB1</em>11:04</td>
<td>GBRA1 SCN8A EFHCI</td>
</tr>
<tr>
<td>67148</td>
<td>tVSPWLVRPKVsashle</td>
<td>HLA-DRB1*11:01</td>
<td>GBRA1 SCN8A EFHCI</td>
</tr>
<tr>
<td>68104</td>
<td>vdlnqskiTLPNdrtpvt</td>
<td>HLA-DQBl*06:02</td>
<td>GPR98</td>
</tr>
<tr>
<td>69149</td>
<td>VIIVHKamdiyNDFMNNftv</td>
<td>HLA-Class II, allele undetermined</td>
<td>CLN5 SCN9A</td>
</tr>
<tr>
<td>69180</td>
<td>vKAKWILgtvntqfqKRSYOm</td>
<td>HLA-DQBl*06:02</td>
<td>LG12 WDR62</td>
</tr>
<tr>
<td>70202</td>
<td>vntqfqKRSYQmysreltoyv</td>
<td>HLA-DRB1*07:01</td>
<td>WDR62</td>
</tr>
<tr>
<td>70165</td>
<td>vntqGAQGIIflfqwrvididd</td>
<td>HLA-Class II, allele undetermined</td>
<td>MK10</td>
</tr>
<tr>
<td>70166</td>
<td>vntqGAQGIIflfqwrvididdftn</td>
<td>B-cell</td>
<td>MK10</td>
</tr>
<tr>
<td>70514</td>
<td>vpyigPALNiVv</td>
<td>HLA-DRB1*11:01</td>
<td>NMDE1</td>
</tr>
<tr>
<td>70982</td>
<td>vsidkfriFCKALnpk</td>
<td>HLA-DRB1*11:01</td>
<td>LRRC1 SCN8A KCMA1</td>
</tr>
<tr>
<td>71155</td>
<td>vstivpyigPALNl</td>
<td>HLA-DR, HLA-DR1, HLA-A*02:01</td>
<td>NMDE1</td>
</tr>
<tr>
<td>71156</td>
<td>vstivpygPALNlqkQGYEGnf</td>
<td>B-cell</td>
<td>NMDE1 TSEAR</td>
</tr>
<tr>
<td>72784</td>
<td>wLVPKVsashelegyqtnyesie</td>
<td>B-cell</td>
<td>SCN8A EFHCI</td>
</tr>
<tr>
<td>76411</td>
<td>ysvidkfriFCKALnpKEE</td>
<td>HLA-Class II, allele undetermined</td>
<td>LRRC1 KCMA1</td>
</tr>
<tr>
<td>76537</td>
<td>yylipvassskdVQLKNitd</td>
<td>HLA-Class II, allele undetermined</td>
<td>GPR98</td>
</tr>
<tr>
<td>79808</td>
<td>elIHVLhgygmgq</td>
<td>HLA-DRA<em>01:01, HLA-DRB1</em>01:01</td>
<td>WDR62 KCMA1</td>
</tr>
<tr>
<td>79816</td>
<td>evyKLVKAKWlgt</td>
<td>HLA-DRA<em>01:01, HLA-DRB1</em>01:01</td>
<td>ARHGA LG12</td>
</tr>
<tr>
<td>113407</td>
<td>fnnftVSPWLVRPKVssas</td>
<td>HLA-DRII</td>
<td>GBRA1 SCN8A EFHCI</td>
</tr>
<tr>
<td>167585</td>
<td>glygmqvssshEIPSkeqiy</td>
<td>HLA-DRB1*12:01</td>
<td>ACH2 ACH4</td>
</tr>
<tr>
<td>167613</td>
<td>kvnqGAQGIIflfqwrvididd</td>
<td>HLA-DRB1*12:01</td>
<td>MK10</td>
</tr>
<tr>
<td>167626</td>
<td>nLISIDnkdyktyndykd</td>
<td>HLA-DRB1*12:01</td>
<td>GPR98</td>
</tr>
<tr>
<td>167666</td>
<td>shEIPSkeiqymhhtypis</td>
<td>HLA-DRB1*12:01</td>
<td>ACH2 ACH4</td>
</tr>
</tbody>
</table>

1One hundred and sixteen linear TT-derived epitopes that had been found to be immunopositive in the human host were analyzed. Epitope number refers to IEDB ID. Further details and references are reported in the Immune Epitope Database (IEDB; http://www.immuneepitope.org/).

2Aa sequences given in one-letter code.

3Peptide fragments shared with epilepsy-associated proteins in capital.

4Epilepsy-associated proteins reported as UniProt/Swiss-prot entries. For details and references, see http://www.uniprot.org/.

5TT-derived epitope ID 76411 shares both pentapeptides FCKAL and PKEE with human KCMA1 (or calcium-activated potassium channel subunit alpha-1).

Acknowledgment

Guglielmo Lucchese is supported by Deutscher Akademischer Austauschdienst (DAAD).

References


